Company

Pathos AI, Inc.

Pathos AI uses oncology data and AI to support drug discovery and development.

About

Pathos AI develops drug discovery tools using real-world oncology and patient-derived functional genomic data to identify and validate biological targets. It works with pharmaceutical and biotechnology companies focused on oncology. Founded in 2022, the company is based in Chicago, US. In October 2024, it raised USD 62 million in Series C funding led by New Enterprise Associates, with participation from Revolution Ventures, Lightbank and Builders VC.

1Funding rounds

4Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in